Program
milvexian
Also written as “BMS-986177”, “Milvexian” and “JNJ-70033093”.
Its studies are mostly in Thrombosis · Ischemic Stroke · Atrial Fibrillation · Acute Coronary Syndrome · Stroke, led by 2 companies.
Drug pageMilvexian: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 140 open or running | phase 2since Dec 20, 2016 | Nov 17, 2015 | none ahead |
| Johnson & Johnson | 112 open or running | phase 3since Jan 19, 2023 | Mar 25, 2019 | Dec 8, 2026phase 3 · NCT05757869 |
- Named in Bristol-Myers Squibb’s own pipeline as
milvexian
, phase 3, as of Oct 29, 2026 (source). - Named in Johnson & Johnson’s own pipeline as
milvexian
, phase 3, as of Oct 13, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentJanssen (Johnson & Johnson) develops it with Bristol Myers Squibb, worldwide, development costs and profits shared.Announced Apr 16, 2018 · Source: Johnson & Johnson, Apr 16, 2018
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Apr 16, 2018Janssen (Johnson & Johnson) develops it with Bristol Myers SquibbCo-developmentWorldwide, development costs and profits shared · announced · Johnson & Johnson
- Mar 25, 2019First study: phase 2 study in Arthroplasty, Replacement, KneeFirst studyNCT03891524 · 1,242 enrolled · United States, Argentina, Belgium and more
- Dec 18, 2019Phase 1 study in HealthyNCT04206488 · 30 enrolled · Belgium
- Jan 8, 2020Phase 1 study in HealthyNCT04223349 · 66 enrolled · United States
- May 12, 2020Phase 1 study in HealthyNCT04388501 · 23 enrolled · Belgium
- Jun 9, 2020Named milvexianINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986177, JNJ-70033093
- Jun 25, 2020Phase 1 study in HealthyNCT04448964 · 24 enrolled · Belgium
- Sep 11, 2020Phase 1 study in HealthyNCT04569695 · 40 enrolled · China
- Apr 12, 2021Phase 1 study in HealthyNCT04844424 · 115 enrolled · United States
- Jan 19, 2023Phase 3 study in Ischemic StrokeNCT05702034 · 12,523 enrolled · United States, Argentina, Australia and more
- Jan 23, 2023Phase 1 study in Healthy FemaleNCT05706753 · 20 enrolled · Belgium
- Feb 23, 20232 phase 3 studiesNCT05754957, NCT05757869
Ahead
- Dec 8, 2026Primary completion: phase 3 study in Atrial FibrillationNCT05757869
TargetBeta
“A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation”study text, read by Claude · the study
Other programs on F11
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abelacimab | anthos-therapeutics-inc | phase 3 | 8 |
| SHR-2004 | Jiangsu HengRui Medicine | phase 3 | 5 |
Studies
All 11 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05757869Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 8, 2026 | 20,284 |
| NCT05754957Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Completed | Feb 6, 2026 | 14,194 |
| NCT05706753Healthy Female · Belgium | 1 | Completed | Jul 20, 2023 | 20 |
| NCT05702034Ischemic Stroke · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 15, 2026 | 12,523 |
| NCT04844424Healthy · United States | 1 | Completed | May 6, 2022 | 115 |
| NCT04569695Healthy · China | 1 | Completed | Dec 4, 2021 | 40 |
| NCT04448964Healthy · Belgium | 1 | Completed | Nov 14, 2020 | 24 |
| NCT04388501Healthy · Belgium | 1 | Completed | Oct 25, 2021 | 23 |
| NCT04223349Healthy · United States | 1 | Completed | Apr 8, 2020 | 66 |
| NCT04206488Healthy · Belgium | 1 | Completed | Jun 9, 2021 | 30 |
| NCT03891524Arthroplasty, Replacement, Knee · United States, Argentina, Belgium and more | 2 | Completed | Apr 6, 2021 | 1,242 |
How it is read
Names in the registry
- “BMS-986177”, 14 entries
- “Milvexian”, 6 entries
- “JNJ-70033093”, 4 entries
- “JNJ-70033093 25 mg”, 1 entry
- “JNJ-70033093 50 mg”, 1 entry
Conditions, from the studies’ own filings
- Thrombosis, 9 studies
- Ischemic Stroke, 2 studies
- Atrial Fibrillation, 1 study
- Acute Coronary Syndrome, 1 study
- Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.